Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.
OBJECTIVE
To determine the influence of clinical, laboratory, and electrodiagnostic factors on the prognosis of Guillain-Barré syndrome (GBS).


BACKGROUND
Identification of prognostic factors may lead to better selection of patients with a poor prognosis for new therapeutic trials.


METHODS
The authors studied 147 patients with GBS who participated in the Dutch GBS trial comparing the effect of IV immunoglobulins with plasma exchange (PE). Outcome was measured at 8 weeks because half of the patients had recovered independent locomotion by then and at 6 months, the endpoint of the study.


RESULTS
Multivariate logistic regression revealed the following factors predicting outcome (inability to walk independently) at 8 weeks: a preceding gastrointestinal illness (yes, no), age (> or =50, <50 years), Medical Research Council sum score (<40, > or =40) at the start of treatment, and-described for the first time-a recent cytomegalovirus (CMV) infection (yes, no). At 6 months, the same clinical factors were found, but an initial rapid progression of weakness also appeared to be a prognostic factor. Analysis of treatment interactions revealed that the effect of diarrhea was more pronounced in the PE-treated group.


CONCLUSIONS
The main predictors of outcome in GBS are clinical factors. Diarrhea is an important poor predictor of outcome, especially for the PE-treated group, and a recent CMV infection predicts delayed early recovery.
Visser
L H
LH
Department of Neurology, University Hospital Dijkzigt/Dr. Daniel den Hoed Cancer Center and Erasmus University, Rotterdam, The Netherlands.
Schmitz
P I
PI
Meulstee
J
J
van Doorn
P A
PA
van der Meché
F G
FG
D004576:Electromyography; D006801:Humans; D016756:Immunoglobulins, Intravenous; D008875:Middle Aged; D010951:Plasma Exchange; D011129:Polyradiculoneuropathy / Q000503:physiopathology* / Q000628:therapy*; D011237:Predictive Value of Tests; D011379:Prognosis; D013997:Time Factors
D016756:Immunoglobulins, Intravenous